Short answer · Medically reviewed summary · Last updated: 2026-04-06
The life expectancy for individuals with Scleroderma varies significantly depending on the specific subtype, the extent of organ involvement, and the timing of clinical intervention. Understanding the Prognosis Because Scleroderma (systemic sclerosis) is a heterogeneous condition, it is impossible to provide a universal life expectancy figure. Many patients lead long, fulfilling lives, while others face complex challenges requiring intensive medical management.
14 people with Scleroderma have shared their first-person experience on this question at DiseaseMaps.
What is the life expectancy of someone with Scleroderma?
Life expectancy with Scleroderma: what research and real patients say, recent advances, and a medically reviewed summary with sources.
The life expectancy for individuals with Scleroderma varies significantly depending on the specific subtype, the extent of organ involvement, and the timing of clinical intervention.
Understanding the Prognosis
Because Scleroderma (systemic sclerosis) is a heterogeneous condition, it is impossible to provide a universal life expectancy figure. Many patients lead long, fulfilling lives, while others face complex challenges requiring intensive medical management. The prognosis is primarily determined by whether the disease remains limited to the skin or involves internal organs, such as the lungs (interstitial lung disease) or the heart.
Factors Influencing Outcomes
Several variables contribute to long-term health in patients with Scleroderma:
- Subtype Classification: Limited cutaneous systemic sclerosis generally follows a more indolent course compared to diffuse cutaneous systemic sclerosis.
- Organ Involvement: Early screening for pulmonary arterial hypertension and interstitial lung disease allows for proactive management, which is crucial for improving survival.
- Treatment Adherence: Modern therapies, including immunosuppressants and targeted vascular treatments, have dramatically improved outcomes compared to several decades ago.
Quality of Life and Modern Care
While longevity is a primary medical focus, our team emphasizes that quality of life is equally vital. Living well with Scleroderma involves managing chronic symptoms like Raynaud’s phenomenon and skin tightness through multidisciplinary care. Regular, longitudinal follow-up with rheumatologists, pulmonologists, and cardiologists ensures that any changes in disease activity are addressed immediately. We have seen significant improvements in survival rates over the last twenty years, thanks to better diagnostic tools and a deeper understanding of the disease's underlying mechanisms. You are not defined by a statistic; you are a unique individual, and the landscape of care for this condition is constantly evolving toward better, more effective interventions.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your rheumatologist or other qualified health provider with any questions regarding your medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Scleroderma
- Orphanet: Systemic Sclerosis
- Scleroderma Foundation: Understanding the Disease
Posted Apr 1, 2017 by Fashah 1150
Posted Apr 1, 2017 by Milda 1000
The most common causes of death in scleroderma patients is lung involvement followed by heart involvement. Kidney failure is less of an issue than it used to be because of the discovery that ACE inhibitors can be very effective in dealing with scleroderma renal crisis (SRC).
Recent research on autologous stem cell transplants (HSCT), a treatment where the immune system is first destroyed and then rebuilt from the patient's own stem cells, suggests that this may be more effective than conventional treatments in patients with rapidly progressing diffuse disease. However, even with optimum patient selection, there is about a 5% mortality rate for the procedure, which is why it is only being tried in patients with poor prognosis.
Recent research on therapeutic plasma exchange suggests that this may be an effective option but more research is needed to verify this.
Posted Apr 4, 2017 by Choclit 1150
Posted Mar 30, 2018 by Amy 2600
Posted Nov 21, 2018 by Juanita 1900
Posted Feb 27, 2017 by cecilia miranda 1000
I don't know that there is no important novelty
Posted Mar 21, 2017 by Amparo 1000
Posted Mar 23, 2017 by ana h 1400
Posted Apr 28, 2017 by Alma Olivia 1000
Posted May 15, 2017 by Lucero 1050
Posted May 18, 2017 by Montse 1151
Posted Sep 30, 2017 by Carol 1000
Posted Nov 22, 2017 by Martín Luis Durán Salamanca 100
